ժҪ �ź�ת����ת¼��������3(signal transducers and activators of transcription 3,STAT3)��һ��ϸ������Ҫ��ת¼����,�����ڿɱ�����������μ�øJAK��ø(Janus kinase)���ữ���������֪,�쳣�����STAT3�ٽ������ķ�����չ,����о���Աһֱ�������о�һ�����JAK/STAT3�ź�ͨ·�Ŀ�����ҩ������ռ��˽����������б����İ���JAK/STAT3�ź�ͨ·�����Ƽ��о����ٴ������չ,���ڲ������Ƽ��Ѿ������İе㡢���û��ƺ�ҩЧ���Խ����ܽᡣ
Abstract��Signal transducers and activators of transcription 3 generally located in cytoplasm is a key intra-cellular transcription. So far, STAT3 has been known that could be activated by several different upstream kinase within cell, the most common one of which is Janus kinase. The aberrant activation of STAT3 induces tumorigenesis and promotes tumor development. Consequently, researchers have always been committed to developing novel anti-tumor drugs targeting JAK/STAT3 pathway signaling. In this review, researches as well as clinical trials of JAK/STAT3 inhibitors published over the past several years are collected and the targets, mechanism and pharmacological properties of certain inhibitors are summarized.
������, ����, ����, ��ï��. JAK/STAT3�ź�ͨ·�������Ƽ�����������������о���չ[J]. �й�ҩѧ��־, 2018, 53(23): 1973-1977.
GUAN Ling-nan, LIU Zhe, WANG Huan, LAI Mao-de. JAK/STAT3 Signaling Pathway and Its Inhibitors in Tumor Therapy. Chinese Pharmaceutical Journal, 2018, 53(23): 1973-1977.
RODIG S J, MERAZ M A, WHITE J M, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell, 1998, 93(3):373-383.
[2]
KREMPLER A, QI Y, TRIPLETT A A, et al. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis, 2004, 40(1):52-57.
[3]
O��SHEA J J, PESU M, BORIE D C, et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov, 2004, 3(7):555-564.
[4]
SANDA T, TYNER J W, GUTIERREZ A, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov, 2013, 3(5):564-577.
[5]
FURTEK S L, BACKOS D S, MATHESON C J, et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol, 2016, 11(2):308-318.
[6]
XU S, NEAMATI N. Gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets, 2013, 17(11):1303-1328.
[7]
XIONG A, YANG Z, SHEN Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers, 2014, 6(2):926-957.
[8]
KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 2002, 285(1-2):1-24.
[9]
YU H, LEE H, HERRMANN A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer, 2014, 14(11):736-746.
[10]
JOHNSON D E, O��KEEFE R A, GRANDIS J R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018, 15(4):234-248.
[11]
CARPENTER R L, LO H W. STAT3 target genes relevant to human cancers. Cancers, 2014, 6(2):897-925.
[12]
AKIRA S, NISHIO Y, INOUE M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell, 1994, 77(1):63.
[13]
YOU W, TANG Q, ZHANG C, et al. IL-26 Promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS One, 2013, 8(5):e63588.
[14]
ZHAO G, ZHANG J G, SHI Y, et al. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One, 2013, 8(9):e73803.
[15]
MCDOUGALL S R, ANDERSON A R A, CHAPLAIN M A J. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol, 2006, 241(3):564-589.
[16]
KALLURI R, ISRAEL B. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer, 2003, 3(6):422-433.
[17]
ZUGOWSKI C, LIEDER F, GASCH J, et al. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem, 2011, 392(5):449-459.
[18]
TSUJITA Y, HORIGUCHI A, TASAKI S, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells. Oncol Rep, 2017, 38(4):2197-2204.
[19]
SNYDER M, HUANG X Y, ZHANG J J. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem, 2011, 286(45):38886-38893.
[20]
LI L, WANG S, YANG X, et al. Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3 / MMP9 pathway. Mol Med Rep, 2017, 16(3):2461-2468.
[21]
NIU G, WRIGHT K L, HUANG M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 2002, 21(13):2000-2008.
[22]
BU L L, YU G T, WU L, et al. STAT3 Induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res, 2017, 96(9):1027-1034.
[23]
LOU W, CHEN Y, ZHU K, et al. Polyphyllin I overcomes EMT-associated resistance to erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition. Biol Pharm Bull, 2017, 40(8):1306-1313.
[24]
ERNST M, BUCHERT M. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies. Semin Cancer Biol, 2017,45:13-22.
[25]
FURQAN M, MUKHI N, LEE B, et al. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res, 2013, 1(1):5.
[26]
HEDVAT M, HUSZAR D, HERRMANN A, et al. The JAK2 inhibitor, AZD1480, potently blocks Stat3 signaling and oncogenesis in solid tumors michael. Cancer Cell, 2010, 16(6):487-497.
[27]
CHAI E Z P, SHANMUGAM M K, ARFUSO F, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther, 2016, 162: 86-97.
[28]
HU Y, DONG X, LIU X, et al. Enhanced antitumor activity of cetuximab in combination with the Jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes. Mol Pharm, 2016, 13(2):689-697.
[29]
OCHI N, ISOZAKI H, TAKEYAMA M, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer. Exp Cell Res, 2016, 344(2):194-200.
[30]
YOUNES A, ROMAGUERA J, FANALE M, et al. Phase I study of a novel oral janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol, 2015, 30(33):4161-4168.
[31]
SAU S, MONDAL S K, KASHAW S K, et al. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. Mol Cell Biochem, 2017,436(1-2):1-18.
[32]
NAM S, WEN W, SCHROEDER A, et al. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol, 2013, 7(3):369-378.
[33]
BRAMBILLA L, GENINI D, LAURINI E, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol, 2015, 9(6):1194-1206.
[34]
HAYAKAWA F, SUGIMOTO K, HARADA Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J, 2013, 3(11):e166.
[35]
WONG A L, SOO R A, TAN D S, et al. Phase �� and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol, 2015, 26(5):998-1005.
[36]
OGURA M, UCHIDA T, TERUI Y, et al. Phase �� study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci, 2015, 106(7):896-901.
[37]
ZHANG X, YUE P, PAGE B D G, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA, 2012, 109(24):9623-9628.
[38]
HUANG W, DONG Z, CHEN Y, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene, 2016, 35(6):783-792.
[39]
LI Y, ROGOFF H A, KEATES S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA, 2015, 112(6):1839-1844.
[40]
CAFFERKEY C, CHAU I. Novel STAT 3 inhibitors for treating gastric cancer. Expert Opin Investig Drugs, 2016, 25(9):1023-1031.
[41]
CHIARLE R, SIMMONS W J, CAI H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med, 2005, 11(6):623-629.
[42]
HONG D, KURZROCK R, KIM Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med, 2015, 7(314):314ra185.
[43]
TIMOFEEVA O A, TARASOVA N I, ZHANG X, et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci USA, 2013, 110(4):1267-1272.
2018, Vol. 53 
